Oslo Pensjonsforsikring AS Makes New $648,000 Investment in Gilead Sciences, Inc. $GILD

Posted by George Bondi on Jul 22nd, 2026

Gilead Sciences logo Oslo Pensjonsforsikring AS acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the 1st quarter, Holdings Channel.com reports. The institutional investor acquired 4,648 shares of the biopharmaceutical company’s stock, valued at approximately $648,000.

A number of other hedge funds also recently made changes to their positions in GILD. Aviva PLC raised its position in shares of Gilead Sciences by 5.4% during the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after purchasing an additional 59,782 shares during the period. Life Cycle Investment Partners Ltd purchased a new position in shares of Gilead Sciences in the fourth quarter valued at about $1,418,000. Beacon Investment Advisory Services Inc. boosted its stake in shares of Gilead Sciences by 10.3% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 111,531 shares of the biopharmaceutical company’s stock worth $13,689,000 after acquiring an additional 10,449 shares during the period. NBC Securities Inc. grew its position in shares of Gilead Sciences by 150.3% during the fourth quarter. NBC Securities Inc. now owns 17,147 shares of the biopharmaceutical company’s stock worth $2,105,000 after purchasing an additional 10,296 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its holdings in Gilead Sciences by 45.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 243,532 shares of the biopharmaceutical company’s stock worth $29,891,000 after purchasing an additional 76,432 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00. Following the completion of the transaction, the chief executive officer owned 607,133 shares in the company, valued at $76,674,826.57. This represents a 2.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 77,000 shares of company stock worth $9,978,740. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $130.28 on Wednesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The company has a market capitalization of $161.75 billion, a PE ratio of 17.75 and a beta of 0.32. The company has a 50 day moving average price of $129.63 and a 200-day moving average price of $135.42. Gilead Sciences, Inc. has a fifty-two week low of $108.06 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post -0.77 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were given a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on GILD shares. Citigroup upped their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a report on Monday, July 6th. Royal Bank Of Canada decreased their price target on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a research note on Tuesday, July 7th. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, April 17th. Finally, Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $158.33.

Read Our Latest Report on GILD

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.